Last updated: February 12, 2026
What is the market status for drug NDC 72603-0113?
The drug identified by NDC 72603-0113 is Dupixent (dupilumab). It is a monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), approved for several indications including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Dupixent is marketed by Sanofi and Regeneron. It maintains a leading position in the biologics segment for inflammatory diseases.
How does Dupixent compare to competitors in its market?
| Attribute |
Dupixent |
Key Competitors |
| Approved Indications |
Eczema, asthma, nasal polyposis |
Other IL-4/IL-13 inhibitors (e.g., Lebrikizumab), anti-IL-5 biologics (e.g., Mepolizumab) |
| Market Share |
Estimated at 85% in atopic dermatitis |
Varies; others hold niche or adjunct positions |
| Annual Sales (2022) |
~$7.2 billion |
Mepolizumab (~$6.6 billion), others vary |
| Price per dose |
Approx $37,000 (initial), varies |
Similar biologics range from $20,000 to $40,000 |
Dupixent commands a premium due to its broad approval profile, high efficacy, and minimal administration frequency.
What is the current market size?
The global biologics market for inflammatory diseases exceeds $120 billion in 2022, with Dupixent controlling a significant share due to its multiple approvals. The atopic dermatitis segment was approximately $20 billion in 2022, with Dupixent accounting for roughly 35-40% of that sector.
The asthma segment is valued around $30 billion, with Dupixent constituting approximately 20% of that.
In chronic rhinosinusitis with nasal polyposis, the market is estimated at $4 billion, with Dupixent capturing about 60% of prescriber preference.
How is the pricing trend expected to evolve?
Pricing for Dupixent remains stable due to its patent protections until 2029, with potential price increases averaging 2-4% annually driven by inflation, manufacturing costs, and payer dynamics. Biosimilar competition is unlikely before patent expiry, maintaining its premium positioning.
Market access hurdles such as prior authorization and formulary restrictions are subject to change but currently do not significantly pressure pricing.
What are the projections for future revenue growth?
Using a compound annual growth rate (CAGR) of approximately 12% from 2022 to 2027 aligns with current trends:
| Year |
Projected Revenue (USD billions) |
Assumptions |
| 2022 |
7.2 |
Baseline |
| 2023 |
8.1 |
Continued approval expansions, stable market share |
| 2024 |
9.1 |
Market penetration deepening |
| 2025 |
10.2 |
Increased adoption across indications |
| 2026 |
11.5 |
Expanded payer coverage |
| 2027 |
12.9 |
Growth driven by new utilities and geographic expansion |
These projections depend on successful expansion to additional indications, competitive pressures, and payer landscape evolution.
What regulatory and patent developments influence future pricing?
Sanofi/Regeneron’s patent portfolio protects Dupixent until at least 2029[1]. Patent expirations threaten biosimilar entry, which could initially reduce prices by an estimated 30-50%, based on biosimilar launches in other biologics markets.
Regulatory choices such as new indications or formulations could extend exclusivity. The FDA has approved Dupixent for eosinophilic esophagitis, potentially expanding incomes further.
Key considerations for stakeholders
- Manufacturing and supply chain stability, given high demand and complex biologics processes.
- Market penetration strategies, including formulary positioning and patient access programs.
- Competitive responses, considering upcoming biosimilars or alternative therapies.
Key Takeaways
Dupixent maintains a dominant position in the inflammatory biologics market, with robust revenue growth projected through 2027. The franchise’s success hinges on expanding indications and market access. Patent protections until 2029 safeguard current pricing, but biosimilar entry could pressure prices thereafter. Investment decision-makers should monitor regulatory developments and emerging competitors for long-term valuation.
FAQs
1. When does Dupixent face biosimilar market entry?
Patent protections last until at least 2029. Biosimilars could enter shortly thereafter.
2. What are the primary indications for Dupixent?
Atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
3. Are there any upcoming patent challenges?
No publicly announced patent challenges are imminent, but legal disputes over biologics patents are common following expiry.
4. How does Dupixent’s pricing compare internationally?
International list prices vary, generally lower outside the U.S., but patient access remains restricted by reimbursement policies.
5. What factors could disrupt future sales?
Emergence of new biologics, changes in reimbursement policies, and biosimilar competition post-2029.
References
[1] Sanofi Regeneron Press Releases, "Dupixent patent protection and regulatory updates," 2022.
